Clinical Trials Logo

Filter by:
NCT ID: NCT04829214 Completed - Subjective Tinnitus Clinical Trials

OTO-313 in Subjects With Unilateral Subjective Tinnitus

Start date: March 22, 2021
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the efficacy of OTO-313 in subjects with unilateral tinnitus and to determine the safety and tolerability of OTO-313 in subjects with unilateral tinnitus.

NCT ID: NCT04828343 Completed - Clinical trials for Healthy Study Participants

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Rozanolixizumab Administered Subcutaneously Via Manual Push Versus Syringe Driver to Healthy Participants

Start date: April 22, 2021
Phase: Phase 1
Study type: Interventional

The purpose of the study is to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of a single subcutaneous (SC) dose of rozanolixizumab administered to healthy participants by manual push (MP) versus (vs) syringe driver.

NCT ID: NCT04828122 Completed - Alzheimer Disease Clinical Trials

Amyloid Prediction in Early Stage Alzheimer's Disease From Acoustic and Linguistic Patterns of Speech

AMYPRED
Start date: November 19, 2020
Phase:
Study type: Observational [Patient Registry]

The primary objective of the study is to evaluate whether a set of algorithms analysing acoustic and linguistic patterns of speech can detect amyloid-specific cognitive impairment in early stage Alzheimer's disease, as measured by the AUC of the receiver operating characteristic (ROC) curve of the binary classifier distinguishing between amyloid positive (Arms 1 and 3) and amyloid negative (Arms 2 and 4) Arms. Secondary objectives include (1) evaluating whether similar algorithms can detect amyloid-specific cognitive impairment in the cognitively normal (CN) and MCI Arms respectively, as measured on binary classifier performance; (2) whether they can detect MCI, as measured on binary classifier performance (AUC, sensitivity, specificity, Cohen's kappa), and the agreement between the PACC5 composite and the corresponding regression model predicting it in all Arms pooled (Wilcoxon signed-rank test, CIA); (3) evaluating variables that can impact performance of such algorithms of covariates from the speaker (age, gender, education level) and environment (measures of acoustic quality).

NCT ID: NCT04828018 Completed - Quality of Life Clinical Trials

Care of the Ageing Veteran Population: Developing an Evidence Base for the Royal Hospital Chelsea Model of Care

Start date: May 11, 2021
Phase:
Study type: Observational

Royal Hospital Chelsea (RHC) has provided a sheltered housing environment alongside integrated health and social care and comradeship for British Army veterans since 1692, following a decree by King Charles II to aid the "relief of veterans broken by age and war" (RHC, 2018). Today approximately 300 In-Pensioners, known globally as 'Chelsea Pensioners' live at RHC. They also have access to an on-site infirmary providing nursing or personal care for up to 68 people (CQC, 2019). RHC is in central London (UK) and comprises of several historical buildings, protected by the organisations Mission Statement to "…safeguard their historic home for the veterans of tomorrow". In-Pensioner's must have served in the British Army as a non-commissioned officer (or have served at least 12 years 'in the ranks' prior to becoming a commissioned officer), be aged 65 or over, be free of any financial obligations to dependents, and at the time of admission be able to live independently. Traditionally a male-only residence, RHC welcomed its first female Army veteran in 2009. There is an absence of evidence to support the impact of care delivery and the Chelsea Pensioner experience, with the only evidence being RHC Annual and Care Quality Commission (CQC) reports which focus on strategic and operational matters rather than the impact of the wider social care or environment. This lack of evidence presents a unique opportunity to evaluate RHC's current service provision, inform future direction and address the hiatus in evidence-based research to quantify the impact of its model of care.

NCT ID: NCT04826185 Completed - Clinical trials for Non-obstructive Hypertrophic Cardiomyopathy

A Study to Evaluate the Safety, Tolerability, and Efficacy of IMB-1018972 in Patients With Non-obstructive Hypertrophic Cardiomyopathy Trial

IMPROVE-HCM
Start date: June 14, 2021
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the safety, tolerability, and potential efficacy of IMB-1018972 in patients with non-obstructive HCM.

NCT ID: NCT04825639 Completed - Sepsis Clinical Trials

Identifying Risk Factors for Developing AKI in Sepsis

Start date: March 15, 2021
Phase:
Study type: Observational [Patient Registry]

A study to evaluate the prevalence of Acute Kidney Injury (AKI) in patients with Diabetic Ketoacidosis (DKA) and sepsis using data collected prospectively to a patient registry. The primary objective is to compare the prevalence of AKI in sepsis and DKA in different age groups in children and investigate the difference in the prevalence of hyperchloremia in the two groups.Secondary objectives are Compare the prevalence of AKI in sepsis and DKA in different age groups in children and investigate the difference in the prevalence of hyperchloremia in the two groups.

NCT ID: NCT04824781 Completed - Paranoia Clinical Trials

Recovery From Paranoia: a Qualitative Exploration

Start date: June 9, 2021
Phase:
Study type: Observational

Paranoia, the experience of undue or excessive mistrust, exists on a continuum which includes suspicious thoughts, ideas of reference, and persecutory delusions. Persecutory delusions refers to strong unfounded fears that others intend harm. These fears are very common. They affect around 70% of patients with schizophrenia. They can be distressing and make day-to-day tasks difficult. However, current treatments are limited and a significant proportion of people do not benefit sufficiently. Therefore, improvements in treatment are needed. A better understanding of the experience of recovery from paranoia will help inform theoretical understanding and treatment development. Currently we do not fully understand what causes paranoia to occur, persist, or end. As such, it is critical to understand the experiences of those who have recovered, in particular what elements encourage recovery. Therefore, the aim of this study is to gain a first-person perspective on how people recover from paranoia and what psychological processes are important for recovery from paranoia. Using a qualitative approach appropriate for exploratory research, semi-structured interviews will be conducted with 12-15 patients who have recovered from paranoia. Interviews will be analysed using interpretative phenomenological analysis, a qualitative research approach which aims to provide insight on how an individual, in a particular situation, makes sense of their experience.

NCT ID: NCT04824118 Completed - Clinical trials for Venous Thromboembolism

Clotting Parameters After Medical Abortion

C-PLAN
Start date: March 26, 2021
Phase:
Study type: Observational

Venous thromboembolism (VTE - blood clots that form in deep veins or in the lungs) has been identified as a leading cause of death in economically developed countries for pregnant and recently-pregnant women. There is evidence that clotting parameters can take up to 6 weeks to return to normal for women who have had term deliveries, however there is an absence of information on time taken for clotting parameters to normalise following abortion. As such, existing guidelines are based solely on expert opinion and recommend durations of VTE prevention from as short as 7 days, up to 6 weeks following abortion. All women are assessed for risk of VTE, but data are needed to inform an evidence-based approach to prevention of VTE in these women. The findings from this pilot study have the potential to inform clinical guidance and possibly a larger study subsequently.

NCT ID: NCT04823910 Completed - Prostate Cancer Clinical Trials

Personalizing Docetaxel Dosing in Advanced Prostate Cancer

PARTNER
Start date: July 6, 2021
Phase:
Study type: Observational

Patients with advanced prostate cancer are often treated with the chemotherapy drug docetaxel. The manufacturers of this drug suggest using the same dose of drug per m² body surface area for all patients. However we know that individuals end up with more or less of the drug circulating in their blood even after they have been given the same dose. A software program (a "Dosing Tool") has been developed to provide information to doctors on how docetaxel will affect individual patients. The program may help doctors to make informed decisions about exactly how much drug to give to different people. The purpose of the PARTNER study is to gather information from blood tests on patients being treated with docetaxel to help in the further development of the Dosing Tool. Some of these blood tests would have been taken anyway as part of patients' routine treatment. Others are extra for this study. Apart from the additional blood tests, everyone who enters the study is treated just as they would normally be if they were not taking part in the study.

NCT ID: NCT04821466 Completed - Oncology Clinical Trials

VR for Symptom Control and Wellbeing

Start date: June 14, 2021
Phase: N/A
Study type: Interventional

To investigate the effect that a Virtual Reality experience can have on patient symptoms and wellbeing for palliative care and oncology inpatients